NOACs in CAD

Atherothrombosis and Residual Risk

"Stable" Patients Remain at Risk for CV Events

Pathobiology of Atherothrombosis

Thrombotic Pathway More Than Antiplatelet Monotherapy

ATLAS ACS 2--TIMI 51

COMPASS Design 27,395 Subjects, 602 Sites, 33 Countries

Clinician Awareness Rivaroxaban Dosing

COMPASS Population

COMPASS CAD Inclusion Criteria

COMPASS Exclusion Criteria

COMPASS Primary Endpoint

COMPASS MACE*

COMPASS Major Bleeding*

FDA New Indication for Rivaroxaban, October 2018

Individual Risk Assessment

COMPASS Primary Endpoint Results Were Consistent Across All Subgroups

Risk Scores in CAD

TIMI Secondary Prevention Risk Score

Predictors of Major Adverse Limb Events From COMPASS

Selecting Appropriate Patients High-Risk Subgroups

Conclusions

Abbreviations

Abbreviations (cont)